MedPath

A verification study of improving on the oral cavity environment of the test food: an open-label trial

Not Applicable
Conditions
Healthy Japanese subjects
Registration Number
JPRN-UMIN000034948
Lead Sponsor
ORTHOMEDICO Inc.
Brief Summary

Morinaga H, Tanaka M. HGH Crystal MD(R) improves the oral environment-an open-label, observational before-after study-. Jpn Pharmacol Ther. 2019; 47(8): 1297-1313.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
11
Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure or myocardial infarction. 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD). 3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases. 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional food/beverage in daily. 5. Subjects who are currently taking medications (including herbal medicines) and dietary supplements. 6. Subjects who use dentures. 7. Subjects who have receiving treatment of periodontosis or with antimicrobial agents within the last three months. 8. Subjects who have receiving dental maintenance care, such as removing dental plaques and dental tartars within the last three months 9. Subjects who are under treatment or diagnosed with any of dental diseases. 10. Subjects who are allergic to medicines and/or the test food related products. 11. Subjects who are pregnant, breast-feeding, or planning to become pregnant. 12. Subjects who have been enrolled in other clinical trials within the last two months before the agreement to participate in this trial or plan to participate another trial during this trial. 13. Subjects who are ineligibility to participate in the study based on the evaluation of the principal physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
A.actinomycetemcomitans (Aa), P.gingivalis (Pg), P.intermedia (Pi), T.forsythensis (Tf), T.denticola (Td), F.nucleatum (Fn) * Measure the values at screening (before consumption) and 1 week after consumption and calculate the amount of change.
Secondary Outcome Measures
NameTimeMethod
1. Visual Analogue Scale (VAS) of subjective symptoms Halitosis, swelling of gums, surface roughness of tooth, oral discomfort, dry mouth, and, stickiness in the mouth 2. The concentration of serum IGF-1 * Measure the values at screening (before consumption) and 1 week after consumption and calculate the amount of change.
© Copyright 2025. All Rights Reserved by MedPath